We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
+$59.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.47%
2 Technology 8.46%
3 Industrials 4.82%
4 Financials 2.07%
5 Consumer Discretionary 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMCR icon
151
Immunocore
IMCR
$1.72B
– –
-36,000
Closed -$1.53M
IMVT icon
152
Immunovant
IMVT
$7.93B
– –
-158,500
Closed -$2.54M
IONS icon
153
Ionis Pharmaceuticals
IONS
$8.6B
– –
-145,476
Closed -$5.7M
JNJ icon
154
CALL
Johnson & Johnson
JNJ
$618B
– –
-200,000
Closed -$32.9M
KALV
155
DELISTED
KalVista Pharmaceuticals
KALV
– –
-258,880
Closed -$6.65M
LRMR icon
156
Larimar Therapeutics
LRMR
$397M
– –
-100,000
Closed -$1.46M
MREO
157
Mereo BioPharma
MREO
$54.7M
– –
-1,312,415
Closed -$4.42M
NVMI
158
Nova
NVMI
$12.4B
– –
-8,556
Closed -$779K
OBIO icon
159
Orchestra BioMed
OBIO
$238M
– –
-100,000
Closed -$1.12M
ORIC icon
160
Oric Pharmaceuticals
ORIC
$1.15B
– –
-169,900
Closed -$4.16M
PANW icon
161
Palo Alto Networks
PANW
$270B
– –
-193,800
Closed -$10.4M
PRGO icon
162
CALL
Perrigo
PRGO
$1.4B
– –
-210,000
Closed -$8.5M
QSI icon
163
CALL
Quantum-Si Incorporated
QSI
$155M
– –
-85,000
Closed -$1.01M
QSI icon
164
Quantum-Si Incorporated
QSI
$155M
– –
-172,396
Closed -$2.06M
TERN
165
DELISTED
Terns Pharmaceuticals
TERN
– –
-70,000
Closed -$1.54M
TIL icon
166
Instil Bio
TIL
$48.3M
– –
-4,750
Closed -$2.38M
TLT icon
167
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
– –
-60,000
Closed -$8.13M
VRTX icon
168
Vertex Pharmaceuticals
VRTX
$121B
– –
-5,530
Closed -$1.19M
WGS icon
169
GeneDx Holdings
WGS
$1.93B
– –
-606
Closed -$298K
ZNTL icon
170
Zentalis Pharmaceuticals
ZNTL
$337M
– –
-175,140
Closed -$7.6M
PVLA
171
Palvella Therapeutics
PVLA
$1.99B
– –
-8,125
Closed -$1.67M
GRTX
172
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-323,348
Closed -$2.85M
ALPN
173
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-198,260
Closed -$2.1M
NBSE
174
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-1,595
Closed -$236K
GMDA
175
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-178,450
Closed -$1.44M
5 6
7
8 9

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $59.5M of net new capital in Q2 2021, opening 41 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 378,642 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $49.7M trimmed.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.